Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban

Damon E Houghton, Ana I Casanegra, Lisa G Peterson, Jordan Cochuyt, David O Hodge, Danielle Vlazny, Robert D McBane, David Froehling, Waldemar E Wysokinski, Damon E Houghton, Ana I Casanegra, Lisa G Peterson, Jordan Cochuyt, David O Hodge, Danielle Vlazny, Robert D McBane, David Froehling, Waldemar E Wysokinski

Abstract

Randomized controlled trials leading to the approval of apixaban and rivaroxaban for venous thromboembolism (VTE) did not include patients with upper extremity deep vein thrombosis (UE-DVT). We sought to evaluate the safety and effectiveness of rivaroxaban and apixaban for the treatment of acute UE-DVT. Consecutive patients with VTE enrolled into the Mayo Clinic VTE Registry, between March 1, 2013 and December 31, 2019, were followed prospectively. Clinical, demographic and imaging data were collected at the time of study recruitment. Patients with a diagnosis of acute UE-DVT who received rivaroxaban, apixaban, LMWH or warfarin were included. Recurrent VTE, major bleeding, clinical-relevant non-major bleeding (CRNMB), and death were assessed at 3-month intervals. During the study period, 210 patients with acute UE-DVT were included; 63 were treated with apixaban, 39 with rivaroxaban, and 108 with LWMH and/or warfarin. Overall 51% had catheter-associated UE-DVT, 60% had a diagnosis of malignancy, and 14% had concurrent pulmonary embolism. Malignancy was more common in patients treated with LMWH/warfarin (67% vs 52%, P = .03). At 3 months of follow up, one (0.9%) recurrent VTE occurred in a patient treated with LMWH/warfarin and one (1.0%) patient treated with apixaban or rivaroxaban (P = .97). Major bleeding occurred in three patients treated with LMWH/warfarin, and in none of those treated with apixaban or rivaroxaban (P = .09). Clinical-relevant non-major bleeding occurred in one patient (0.9%) treated with LWMH/warfarin and two patients (2.0%) treated with apixaban or rivaroxaban (P = .53). Treatment of UE-DVT with apixaban or rivaroxaban appears to be as safe and effective as LMWH/warfarin.

© 2020 Wiley Periodicals, Inc.

References

REFERENCES

    1. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.
    1. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808.
    1. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352.
    1. Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415.
    1. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2019;18:411-421.
    1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest J. 2012;141(suppl 2):419-494.
    1. Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257-3291.
    1. Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013;11(1):71-80.
    1. Winters JP, Callas PW, Cushman M, Repp AB, Zakai NA. Central venous catheters and upper extremity deep vein thrombosis in medical inpatients: the Medical Inpatients and Thrombosis (MITH) Study. J Thromb Haemost. 2015;13(12):2155-2160.
    1. Joffe HV, Kucher N, Tapson VF, Goldhaber SZ, Deep Vein Thrombosis FSC. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation. 2004;110(12):1605-1611.
    1. Munoz FJ, Mismetti P, Poggio R, et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest. 2008;133(1):143-148.
    1. Cote LP, Greenberg S, Caprini JA, et al. Comparisons between upper and lower extremity deep vein thrombosis: a review of the RIETE registry. Clin Appl Thromb Hemost. 2017;23(7):748-754.
    1. Yamashita Y, Morimoto T, Amano H, et al. Deep vein thrombosis in upper extremities: clinical characteristics, management strategies and long-term outcomes from the COMMAND VTE Registry. Thromb Res. 2019;177(Circulation 107 23 Suppl 1 2003):1-9.
    1. Grant JD, Stevens SM, Woller SC, et al. Diagnosis and management of upper extremity deep-vein thrombosis in adults. Thromb Haemost. 2012;108(6):1097-1108.
    1. Prandoni P, Bernardi E, Marchiori A, et al. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. BMJ. 2004;329(7464):484-485.
    1. Rokosh RS, Ranganath N, Yau P, et al. High prevalence and mortality associated with upper extremity deep venous thrombosis in hospitalized patients at a tertiary care center. Ann Vasc Surg. 2019;65:55-65.
    1. Kahn SR, Galanaud JP, Vedantham S, Ginsberg JS. Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis. 2016;41(1):144-153.
    1. Lazo-Langner A. Studies in upper extremity deep vein thrombosis: addressing the knowledge gaps. Res Pract Thromb Haemost. 2019;3(3):312-314.
    1. Bott-Kitslaar DM, McBane RD, Casanegra AI, et al. Apixaban and rivaroxaban in patients with acute venous thromboembolism. Mayo Clin Proc. 2019;94(7):1242-1252.
    1. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
    1. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119-2126.
    1. Fan FL, Zou YL, Zhang SL, et al. Rivaroxaban in the treatment of PICC-associated upper extremity venous thrombosis. Clin Ther. 2017;39(9):1882-1888.
    1. Davies GA, Lazo-Langner A, Gandara E, et al. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2). Thromb Res. 2018;162:88-92.
    1. Montiel FS, Ghazvinian R, Gottsater A, Elf J. Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J. 2017;15(1):26.
    1. Ageno W, Haas S, Weitz JI, et al. Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE registry. Thromb Haemost. 2019;119(8):1365-1372.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere